https://www.lifordi.com/lifordi-focuses-on-autoimmune-diseases/ 2026-03-12T18:33:26+00:00 https://www.lifordi.com/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors/ 2026-03-12T18:34:10+00:00 https://www.lifordi.com/lifordi-immunotherapeutics-presents-nonclinical-data-on-glucocorticoid-antibody-drug-conjugate-lfd-200-at-acr-2025-and-initiates-phase-1-study-in-rheumatoid-arthritis/ 2026-03-12T18:35:50+00:00 https://www.lifordi.com/lifordi-immunotherapeutics-to-present-new-preclinical-data-on-antibody-drug-conjugate-lfd-200-demonstrating-selective-and-sustained-delivery-of-glucocorticoid-payload-to-immune-tissues-without-evidenc/ 2026-03-12T18:36:29+00:00 https://www.lifordi.com/lifordi-immunotherapeutics-appoints-matthew-w-mcclure-m-d-as-chief-medical-officer/ 2026-03-12T18:37:50+00:00 https://www.lifordi.com/lifordi-named-winner-of-endpoints-11-as-developer-of-antibody-drug-conjugates-for-autoimmune-and-inflammatory-diseases/ 2026-03-12T18:38:45+00:00 https://www.lifordi.com/lfd-200-an-antibody-drug-conjugate-that-selectively-delivers-a-glucocorticoid-payload-to-immune-cells-provides-sustained-anti-inflammatory-effects-without-systemic-toxicity-in-non-human-primates/ 2026-03-12T20:58:25+00:00 https://www.lifordi.com/immune-targeted-glucocorticoid-adc-for-the-treatment-of-autoimmune-and-inflammatory-diseases/ 2026-03-12T20:58:58+00:00 https://www.lifordi.com/arthur-tzianabos-ph-d/ 2026-03-16T17:43:16+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/arthur-tzianabos.png https://www.lifordi.com/naina-bhasin-ph-d/ 2026-03-16T17:43:40+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/naina-bhasin.png https://www.lifordi.com/matthew-w-mcclure-m-d/ 2026-03-16T17:43:46+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/matthew-mcclure.png https://www.lifordi.com/theresa-mcneely/ 2026-03-16T17:43:52+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/theresa-mcneely.png https://www.lifordi.com/dave-nichols/ 2026-03-16T17:43:57+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/dave-nichols.png https://www.lifordi.com/rex-l-williams-ph-d/ 2026-03-16T17:44:08+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/rex-williams.png https://www.lifordi.com/katie-spielberg-ph-d/ 2026-03-16T17:47:48+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/katie-spielberg.png https://www.lifordi.com/l-mary-smith-ph-d/ 2026-03-16T17:47:55+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/l-mary-smith.png https://www.lifordi.com/david-delucia/ 2026-03-16T17:48:05+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/david-delucia.png https://www.lifordi.com/bruce-booth-d-phil/ 2026-03-16T17:48:12+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/bruce-booth.png https://www.lifordi.com/steve-gillis-ph-d/ 2026-03-16T17:48:19+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/steve-gillis.png https://www.lifordi.com/lauren-s-baker-ph-d/ 2026-03-16T17:51:42+00:00 https://www.lifordi.com/jay-rothstein-ph-d/ 2026-03-16T18:09:16+00:00 https://www.lifordi.com/wp-content/uploads/2026/03/jay-rothstein.png https://www.lifordi.com/american-college-of-rheumatology-convergence-2025/ 2026-05-13T23:01:26+00:00 https://www.lifordi.com/stifel-2025-virtual-immunology-and-inflammation-summit-forum/ 2026-05-13T23:01:57+00:00 https://www.lifordi.com/stifel-2024-virtual-immunology-and-inflammation-summit/ 2026-05-13T23:02:11+00:00 https://www.lifordi.com/michael-weinblatt-m-d/ 2026-05-13T23:05:24+00:00 https://www.lifordi.com/stanley-b-cohen-m-d/ 2026-05-13T23:05:54+00:00 https://www.lifordi.com/niti-goel-m-d/ 2026-05-13T23:06:34+00:00 https://www.lifordi.com/l-mary-smith-ph-d-2/ 2026-05-13T23:06:59+00:00 https://www.lifordi.com/peter-a-merkel-m-d-m-p-h/ 2026-05-13T23:07:23+00:00 https://www.lifordi.com/lifordi-immunotherapeutics-presents-preclinical-data-on-glucocorticoid-antibody-drug-conjugate-lfd-200-to-treat-autoimmune-and-inflammatory-diseases-at-eular-2025/ 2026-05-21T20:10:19+00:00 https://www.lifordi.com/lifordi-applying-adcs-to-autoimmune-conditions/ 2026-05-21T20:11:11+00:00 https://www.lifordi.com/lfd-200-an-antibody-drug-conjugate-that-selectively-delivers-a-glucocorticoid-payload-to-immune-cells-has-a-favorable-risk-benefit-profile-vs-prednisone-and-placebo-in-a-first-in-human-study-2/ 2026-06-06T09:30:40+00:00 https://www.lifordi.com/lifordi-immunotherapeutics-presents-phase-1-clinical-data-for-lfd-200-a-subcutaneous-glucocorticoid-antibody-drug-conjugate-at-eular-2026/ 2026-06-08T11:31:40+00:00